{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:24Z","timestamp":1782417504126,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016853","name":"Lysosomal Disease Network","doi-asserted-by":"publisher","award":["2U54NS065768-06"],"award-info":[{"award-number":["2U54NS065768-06"]}],"id":[{"id":"10.13039\/100016853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PRO0001562"],"award-info":[{"award-number":["PRO0001562"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010559","name":"Children's Hospital of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016650","name":"Rare Diseases Clinical Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","gimopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine Open"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gimo.2025.103478","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:54:09Z","timestamp":1764896049000},"page":"103478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease"],"prefix":"10.1016","volume":"4","author":[{"given":"Ankit K.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Rodriguez-Rassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhag","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana Sanchez","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kronn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Austin","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damara","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"McPheron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Lydigsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"DeArmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-909X","authenticated-orcid":false,"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gimo.2025.103478_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.gimo.2025.103478_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.gimo.2025.103478_bib3","first-page":"76","article-title":"Clinical Laboratory experience of blood CRIM testing in infantile Pompe disease","volume":"5","author":"Bali","year":"2015","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gimo.2025.103478_bib5","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience","volume":"160C","author":"Bali","year":"2012","journal-title":"Am J Med Genet C"},{"key":"10.1016\/j.gimo.2025.103478_bib7","article-title":"Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"8","key":"10.1016\/j.gimo.2025.103478_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"issue":"1727","key":"10.1016\/j.gimo.2025.103478_bib10","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3389\/fimmu.2020.01727","article-title":"Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort","volume":"11","author":"Desai","year":"2020","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.gimo.2025.103478_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.gimo.2025.103478_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41436-018-0270-7","article-title":"An immune tolerance approach using transient low-dose methotrexate in the ERT-naive setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease","volume":"21","author":"Kazi","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.gimo.2025.103478_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1360369","article-title":"An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation","volume":"15","author":"Desai","year":"2024","journal-title":"Front Immunol"},{"issue":"1-2","key":"10.1016\/j.gimo.2025.103478_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gimo.2025.103478_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.gimo.2025.103478_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.gimo.2025.103478_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gimo.2025.103478_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-023-02981-2","article-title":"Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry","volume":"18","author":"Kishnani","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.gimo.2025.103478_bib21","first-page":"1","article-title":"Pompe disease treatment with twice a week high dose alglucoside alfa in a patient with severe dilated cardiomyopathy","volume":"16","author":"Landis","year":"2018","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.gimo.2025.103478_bib22","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.gimo.2025.103478_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.gimo.2025.103478_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.gimo.2025.103478_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.a.36197","article-title":"A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment","volume":"164A","author":"Yang","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"5","key":"10.1016\/j.gimo.2025.103478_bib27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ijns6010004","article-title":"Newborn screening for Pompe disease in Illinois: experience with 684,290 infants","volume":"6","author":"Burton","year":"2020","journal-title":"Int J Neonatal Screen"},{"issue":"4","key":"10.1016\/j.gimo.2025.103478_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/ijns6040089","article-title":"Newborn screening for Pompe disease: Pennsylvania experience","volume":"6","author":"Ficicioglu","year":"2020","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ijns6010011","article-title":"Lessons learned from Pompe disease newborn screening and follow-up","volume":"6","author":"Klug","year":"2020","journal-title":"Int J Neonatal Screen"},{"issue":"3","key":"10.1016\/j.gimo.2025.103478_bib31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","article-title":"The New York pilot newborn screening program for lysosomal storage diseases: report of the first 65,000 infants","volume":"21","author":"Wasserstein","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.gimo.2025.103478_bib32","first-page":"30","article-title":"Immune tolerance strategies in siblings with infantile Pompe disease-advantages for a preemptive approach to high-sustained antibody titers","volume":"4","author":"Stenger","year":"2015","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"10.1016\/j.gimo.2025.103478_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr Neonatol"},{"issue":"1","key":"10.1016\/j.gimo.2025.103478_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.gimo.2025.103478_bib35","first-page":"133","article-title":"CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy","volume":"9","author":"Khallaf","year":"2013","journal-title":"JIMD Rep"},{"issue":"3","key":"10.1016\/j.gimo.2025.103478_bib36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02238520","article-title":"Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children","volume":"12","author":"Vogel","year":"1991","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.gimo.2025.103478_bib37","article-title":"Optimizing clinical outcomes: the journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation","volume":"41","author":"Fares","year":"2024","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.gimo.2025.103478_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gimo.2025.103478_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108121","article-title":"Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naive adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the Phase 3 COMET Trial","volume":"141","author":"Toscano","year":"2024","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.gimo.2025.103478_bib40","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","article-title":"104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)","volume":"271","author":"Schoser","year":"2024","journal-title":"J Neurol"}],"container-title":["Genetics in Medicine Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949774425015171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949774425015171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:18:24Z","timestamp":1773411504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949774425015171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":40,"alternative-id":["S2949774425015171"],"URL":"https:\/\/doi.org\/10.1016\/j.gimo.2025.103478","relation":{},"ISSN":["2949-7744"],"issn-type":[{"value":"2949-7744","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gimo.2025.103478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"103478"}}